Risk factors for recurrent Clostridium difficile infection (CDI) hospitalization among hospitalized patients with an initial CDI episode: a retrospective cohort study

Marya D Zilberberg, Kimberly Reske, Margaret Olsen, Yan Yan, Erik R Dubberke, Marya D Zilberberg, Kimberly Reske, Margaret Olsen, Yan Yan, Erik R Dubberke

Abstract

Background: Recurrent Clostridium difficile infection (rCDI) is observed in up to 25% of patients with an initial CDI episode (iCDI). We assessed risk factors for rCDI among patients hospitalized with iCDI.

Methods: We performed a retrospective cohort study at Barnes-Jewish Hospital from 1/1/03 to 12/31/09. iCDI was defined as a positive toxin assay for C. difficile with no CDI in previous 60 days, and rCDI as a repeat positive toxin ≤42 days of stopping iCDI treatment. Three demographic, 13 chronic and 12 acute disease characteristics, and 21 processes of care were assessed for association with rCDI. Cox modeling identified independent risk factors for rCDI.

Results: 425 (10.1%) of 4,200 patients enrolled developed rCDI. Of the eight risk factors for rCDI on multivariate analyses, the strongest three were 1) high-risk antimicrobials following completion of iCDI treatment (HR 2.95, 95% CI 2.25-3.86), 2) community-onset healthcare-associated iCDI (HR 1.80, 95% CI 1.41-2.29) and 3) fluoroquinolones after completion of iCDI treatment (HR 1.56, 95% CI 1.63-2.08). Other risk factors included gastric acid suppression, ≥2 hospitalizations within prior 60 days, age, and IV vancomycin after iCDI treatment ended.

Conclusions: The rCDI rate was 10.1%. Recognizing such modifiable risk factors as certain antimicrobial treatments and gastric acid suppression may help optimize prevention efforts.

References

    1. Pépin J, Valiquette L, Alary ME, Villemure P, Pelletier A, Forget K, Pépin K, Chouinard D. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ. 2004;14:466–472. doi: 10.1503/cmaj.1041104.
    1. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996–2003. Emerg Infect Dis. 2006;14:409–415. doi: 10.3201/eid1205.051064.
    1. Zilberberg MD, Shorr AF, Kollef MH. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000–2005. Emerg Infect Dis. 2008;14:929–931. doi: 10.3201/eid1406.071447.
    1. Lucado, J. (Social & Scientific Systems), Gould, C. (CDC), and Elixhauser, A. (AHRQ) Clostridium difficile Infections (CDI) in Hospital Stays, 2009. HCUP Statistical Brief #124. 2012. Agency for Healthcare Research and Quality, Rockville, MD. .
    1. Clements AC, Magalhaes RJ, Tatem AJ, Paterson DL, Riley TV. Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet Incect Dis. 2010;14:395–404. doi: 10.1016/S1473-3099(10)70080-3.
    1. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA) Infect Control Hosp Epidemiol. 2010;14(5):431–455. doi: 10.1086/651706.
    1. Garey KW, Sethi S, Yadav Y, DuPont HL. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect. 2008;14:298–304. doi: 10.1016/j.jhin.2008.08.012.
    1. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK. OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;14:422–431. doi: 10.1056/NEJMoa0910812.
    1. Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, Sears P, Gorbach S. OPT-80-004 Clinical Study Group. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012;14:281–289. doi: 10.1016/S1473-3099(11)70374-7.
    1. Fekety R, McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Mulligan ME. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis. 1997;14:324–333. doi: 10.1093/clinids/24.3.324.
    1. McFarland LV, Surawicz CM, Rubin M, Fekety R, Elmer GW, Greenberg RN. Recurrent Clostridium difficile: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol. 1999;14:43–50. doi: 10.1086/501553.
    1. Cadle RM, Mansouri MD, Logan N, Kudva DR, Musher DM. Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis. Am J Health Syst Pharm. 2007;14:2359–2363. doi: 10.2146/ajhp060629.
    1. Kim JW, Lee KL, Jeong JB, Kim BG, Shin S, Kim JS, Jung H, Son IS. Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrhea. World J Gastroenterol. 2010;14:3573–3577. doi: 10.3748/wjg.v16.i28.3573.
    1. Zilberberg MD, Tabak YP, Sievert DM, Derby KG, Johannes RS, Sun X, McDonald LC. Using electronic health information to risk-stratify rates of Clostridium difficile infection in US hospitals. Infect Control Hosp Epidemiol. 2011;14:649–655. doi: 10.1086/660360.
    1. Eyre DW, Walker AS, Wylie D, Dingle KE, Griffiths D, Finney J, O'Connor L, Vaughan A, Crook DW, Wilcox MH, Peto TE. Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin Infect Dis. 2012;14:S77–S87. doi: 10.1093/cid/cis356.
    1. McDonald LC, Coignard B, Dubberke E, Song X, Horan T, Kutty PK. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol. 2007;14:140–145. doi: 10.1086/511798.
    1. Dubberke ER, Reske KA, Yan Y, Olsen MA, McDonald LC, Fraser VJ. Clostridium difficile–associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis. 2007;14:1543–1549. doi: 10.1086/523582.
    1. Dubberke ER, Yan Y, Reske KA, Butler AM, Doherty J, Pham V, Fraser VJ. Development and validation of a Clostridium difficile infection risk prediction model. Infect Control Hosp Epidemiol. 2011;14:360–366. doi: 10.1086/658944.
    1. Hosmer DW, Lemeshow S. In: Applied Logistic Regression. 2. New York, NY, editor. New York, NY: John Wiley and Sons, Inc; 2000.
    1. Harrell FE Jr, Margolis PA, Gove S, Mason KE, Mulholland EK, Lehmann D, Muhe L, Gatchallan S, Eichenwald HF. Development of a clinical prediction model for an ordinal outcome: the World Health Organization Multicentre Study of Clinical Signs and Etiological agents of Pneumonia, Sepsis and Meningitis in Young Infants. WHO/ARI Young Infant Multicentre Study Group. Stat Med. 1998;14:909–944. doi: 10.1002/(SICI)1097-0258(19980430)17:8<909::AID-SIM753>;2-O.
    1. SAS. Copyright (c) 2002–2010. Cary, NC, USA: SAS Institute Inc;
    1. Kim YG, Graham DY, Jang BI. Proton pump inhibitor use and recurrent Clostridium difficile-associated disease: a case–control analysis matched by propensity score. J Clin Gastroenterol. 2012;14:397–400. doi: 10.1097/MCG.0b013e3182431d78.
    1. Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenetrol. 2012;14:1011–1019. doi: 10.1038/ajg.2012.108.
    1. Tleyjeh IM, Abdulhak AB, Riaz M, Garbati MA, Al-Tannir M, Alasmari FA, Alghamdi M, Khan AR, Erwin PJ, Sutton AJ, Baddour LM. The association between histamine 2 receptor antagonist use and Clostridium difficile infection: a systematic review and meta-analysis. PLoS One. 2013;14:e56498. doi: 10.1371/journal.pone.0056498.
    1. Mullane KM, Miller MA, Weiss K, Lentnek A, Golan Y, Sears PS, Shue YK, Louie TJ, Gorbach SL. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis. 2011;14:440–447. doi: 10.1093/cid/cir404.
    1. Pépin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, Leblanc M, Rivard G, Bettez M, Primeau V, Nguyen M, Jacob CE, Lanthier L. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;14:1254–1260. doi: 10.1086/496986.
    1. Petrella LA, Sambol SP, Chenknis A, Nagaro K, Kean Y, Sears PS, Babakhani F, Johnson S, Gerding DN. Decreased cure and increased recurrence rates for Clostridium difficile Infection caused by the epidemic C. difficile BI strain. Clin Infect Dis. 2012. [Epub ahead of print]
    1. Sethi AK, Al-Nassir WN, Nerandzic MM, Bobulsky GS, Donskey CJ. Persistence of skin contamination and environmental shedding of Clostridium difficile during and after treatment of C. difficile infection. Infect Control Hosp Epidemiol. 2010;14:21–27. doi: 10.1086/649016.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren